COX-2 inhibition by diclofenac is associated with decreased apoptosis and lesion area after experimental focal penetrating traumatic brain injury in rats by Jadid, Kayvan Dehlaghi et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
COX-2 inhibition by diclofenac is associated with decreased apoptosis and lesion area
after experimental focal penetrating traumatic brain injury in rats
Jadid, Kayvan Dehlaghi; Davidsson, Johan; Lidin, Erik; Hanell, Anders; Angeria, Maria;
Mathiesen, Tiit; Risling, Marten; Gunther, Mattias
Published in:
Frontiers in Neurology
DOI:
10.3389/fneur.2019.00811
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Jadid, K. D., Davidsson, J., Lidin, E., Hanell, A., Angeria, M., Mathiesen, T., ... Gunther, M. (2019). COX-2
inhibition by diclofenac is associated with decreased apoptosis and lesion area after experimental focal
penetrating traumatic brain injury in rats. Frontiers in Neurology, 10, [811].
https://doi.org/10.3389/fneur.2019.00811
Download date: 04. Feb. 2020
ORIGINAL RESEARCH
published: 30 July 2019
doi: 10.3389/fneur.2019.00811
Frontiers in Neurology | www.frontiersin.org 1 July 2019 | Volume 10 | Article 811
Edited by:
Stefania Mondello,
University of Messina, Italy
Reviewed by:
Francisco Capani,
University of Buenos Aires, Argentina
Niklas Marklund,
Lund University, Sweden
*Correspondence:
Mattias Günther
mattias.gunther@ki.se
Specialty section:
This article was submitted to
Neurotrauma,
a section of the journal
Frontiers in Neurology
Received: 23 September 2018
Accepted: 15 July 2019
Published: 30 July 2019
Citation:
Dehlaghi Jadid K, Davidsson J,
Lidin E, Hånell A, Angéria M,
Mathiesen T, Risling M and Günther M
(2019) COX-2 Inhibition by Diclofenac
Is Associated With Decreased
Apoptosis and Lesion Area After
Experimental Focal Penetrating
Traumatic Brain Injury in Rats.
Front. Neurol. 10:811.
doi: 10.3389/fneur.2019.00811
COX-2 Inhibition by Diclofenac Is
Associated With Decreased
Apoptosis and Lesion Area After
Experimental Focal Penetrating
Traumatic Brain Injury in Rats
Kayvan Dehlaghi Jadid 1, Johan Davidsson 2, Erik Lidin 1, Anders Hånell 1, Maria Angéria 1,
Tiit Mathiesen 3,4, Mårten Risling 1 and Mattias Günther 1*
1 Experimental Traumatology Unit, Department of Neuroscience, Karolinska Institutet, Solna, Sweden, 2Division of Vehicle
Safety, Department of Mechanics and Maritime Sciences, Chalmers University of Technology, Gothenburg, Sweden,
3Department of Clinical Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 4Department of Clinical
Neuroscience, Karolinska Institutet, Solna, Sweden
Traumatic brain injury (TBI) is followed by a secondary inflammation in the brain.
The inflammatory response includes prostanoid synthesis by the inducible enzyme
cyclooxygenase-2 (COX-2). Inhibition of COX-2 is associated with improved functional
outcome in experimental TBI models, although central nervous system-specific effects
are not fully understood. Animal studies report better outcomes in females than
males. The exact mechanisms for this gender dichotomy remain unknown. In an initial
study we reported increased COX-2 expression in male rats, compared to female,
following experimental TBI. It is possible that COX-2 induction is directly associated with
increased cell death after TBI. Therefore, we designed a sequential study to investigate
the blocking of COX-2 specifically, using the established COX-2 inhibitor diclofenac.
Male Sprague-Dawley rats weighing between 250 and 350 g were exposed to focal
penetrating TBI and randomly selected for diclofenac treatment (5 µg intralesionally,
immediately following TBI) (n = 8), controls (n = 8), sham operation (n = 8), and normal
(no manipulation) (n = 4). After 24 h, brains were removed, fresh frozen, cut into 14µm
coronal sections and subjected to COX-2 immunofluorescence, Fluoro Jade, TUNEL,
and lesion area analyses. Diclofenac treatment decreased TUNEL staining indicative of
apoptosis with a mean change of 54% (p < 0.05) and lesion area with a mean change of
55% (p < 0.005). Neuronal degeneration measured by Fluoro Jade and COX-2 protein
expression levels were not affected. In conclusion, COX-2 inhibition by diclofenac was
associated with decreased apoptosis and lesion area after focal penetrating TBI and may
be of interest for further studies of clinical applications.
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INTRODUCTION
Traumatic brain injury (TBI) is a leading cause of mortality
and morbidity worldwide (1). The primary trauma is followed
by a secondary inflammatory process that may extend for
weeks, involving a multitude of inflammatory mediators
(2, 3). Cyclooxygenases (COX) are enzymes that form pro-
inflammatory prostanoids from arachidonic acid (4). COX-1
is the constitute isoform while COX-2 is induced by growth
factors, cytokines, and inflammatory mediators (5). TBI leads
to immediate induction of COX-2 in rat brains, persisting
for more than 12 days. COX-2 activity reduces prostaglandin,
prostacyclin, and thromboxane products in the brain (6, 7).
While COX-2 inhibitors improve cognitive functions and motor
performance, the exact function of COX-2 in posttraumatic
neuroinflammation is unclear (8–10). Human studies report
worse outcomes in women than men after TBI, whereas animal
studies report better outcomes in females than males (11). The
mechanisms for a possible gender dichotomy remain unknown.
In an initial study we reported increased COX-2 expression
in male rats compared to female after experimental TBI. The
increased COX-2 expression correlated with increased apoptotic
cell death detected by TUNEL staining at 24 h, while neuronal
necrosis was not observed (12). Due to the possibility of COX-
2 induction being directly associated with increased apoptosis
after TBI a sequential study to investigate blocking of COX-2
specifically was designed, using the established COX-2 inhibitor
diclofenac, in an identical model of focal penetrating TBI (13).
The penetrating trauma also allowed for direct administration
of diclofenac within the perilesional area. Markers of neuronal
degeneration and apoptosis at 24 h after injury, corresponding
to the peak of post traumatic inflammation in the brain, were
analyzed (14, 15).
MATERIALS AND METHODS
The study was conducted in accordance with the Swedish
regional Ethics Approval Board for Animal Research (N81/13). A
total of 28 male Sprague-Dawley rats (Harlan UK LTD) weighing
between 250 and 350 g were divided into the following four
groups: experimental trauma+ diclofenac treatment (treatment;
n = 8), experimental trauma and NaCl (controls; n = 8),
anesthesia and surgery without trauma (sham; n = 8), and naïve
animals without any manipulation (normal; n = 4). The rats
were exposed to penetrating focal brain injury as described by
Plantman et al. (13) and sacrificed after 24 h. Briefly, the rats
were anesthetized by 4% isoflurane and buprenorphine 50µg/kg.
In each rat, a midline incision was made through the skin and
periosteum, and a burr hole 2.7mm in diameter was drilled with
its center 3mm lateral and 3mm posterior to bregma. Each rat
in the experimental trauma and sham groups was placed in a
stereotactic frame and positioned with the probe directly above
the dura mater. A lead pellet was accelerated by air pressure,
hitting a metal cylinder probe with an attached carbon fiber
pin, with a tip radius of 1mm. Depth of penetration into the
brain by the pin was limited to 5mm. Sham operated animals
were subjected to identical treatment except for the penetrating
injury. Diclofenac (2-(2,6-dichloranilino) phenylacetic acid), 5
µg in 5 µl 0.9% NaCl, was administered immediately following
the trauma in the injury cavity in treatment group, and 5 µl 0.9%
NaCl was administered in the injury cavity in the “control” group.
In the “treatment” and “control” groups, a 23-gauge needle with
a 1mL plastic syringe (Becton, Dickinson and Company) was
inserted 4mm into the cavity and the injection was performed
manually with gentle pressure while the needle was carefully
withdrawn from the cavity. The total volume was injected
without signs of leakage outside the burr hole in any rat. The
timing of the injection, equipment used, injection speed, position
of the tip of the syringe and total volumes were identical in all
animals receiving injections. The dosage was based on previous
reports of rodent brain administration of diclofenac (16, 17). The
skin lesion was sutured after the drug administration.
The rats were sacrificed by an overdose of pentobarbital,
brains were fresh frozen and cut into 14-µm coronal sections
using a Microm HM560 cryostat. Each section was cut starting
from the level of the trauma, at the level of corpus callosum
being visible, approximately at bregma −2.3mm, and mounted
onto Thermo Scientific Superfrost plus slides and stored at
−70◦C. The region of interest (ROI) was defined medially by
the interhemispheric fissure and the midline, basally by the
perilesional area and laterally by the lateral border of the right
hemisphere (Figures 1A,B). The central necrotic part of the
contusion was omitted from the ROI. The slides were blinded to
the assessor in all quantifications.
For evaluation of lesion volume, slides from each rat in
treatment and control groups were obtained from bregma+0.48,
bregma +0.7, bregma +1.0, bregma +1.2, bregma +1.6, and
bregma+1.7 for comparison. The lesion areas were calculated at
each level in every rat; the assessor was blinded to the treatment
group. The lesion areas at each level were compared between
the groups and an aggregated mean difference was obtained
as a mean difference of the differences at the six different
levels. For COX-2 immunofluorescent detection, the slides were
rehydrated in phosphate buffer saline (PBS), fixated for 60min
with 4% formalin, and blocked in the solution of 1% bovine
serum albumin (BSA), 0.3% Triton X-100 and NaN3 (NaAz).
The sections were then incubated with the primary antibody
(COX-2, dilution 1:100, ab15191 lot: GR146689-1, ABCAM)
overnight at 4◦C. Next, the slides were incubated with the
secondary antibody (Alexa Fluor 488, dilution 1:500, 711-545-
152 Jackson ImmunoResearch Laboratories, INC). The nuclear
marker used was 4
′
,6-diamidino-2-phenylindole (DAPI). The
TACS 2 TdT- Blue Label in situ Apoptosis Detection Kit, by
Terminal Deoxynucleotidyl transefarse dUTP nick end labeling
(TUNEL), was used for the detection of apoptosis in the tissue
sections. The slides were put on a heated plate for 30min
and then fixated in 3.7% formaldehyde. The slides were then
permeabilized in ethanol for 5min in −20◦C and put in a
quenching solution (94ml methanol and 6ml 50% hydrogen
peroxide) for 5min before being treated with TdT labeling,
incubated for 60min at 37◦C and stopped with a 1XTdT
stop buffer. Before detection, the slides were incubated with
Streptavidin-HRP (1:500) for 20min and followed by counter
staining with Nuclear Fast Red for 2min. The slides were then
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FIGURE 1 | (A) Coronal projection of a rat brain, showing the area of penetrating injury and the region of interest for quantification of COX-2, TUNEL, and Fluoro Jade.
Diclofenac was injected in the trauma cavity directly after injury. (B) Sagittal projection 1.44mm laterally of the midline of a rat brain showing the central necrosis and
perilesional area. Lesion area was measured at comparable sections at bregma +0.48, +0.7, +1.0, +1.2, +1.6, +1.7mm (black arrows) representing the frontal part
of the perilesional area.
dehydrated in a series of dH2O, 70% ethanol, 90% ethanol, 100%
ethanol and xylene, and finally mounted in Entellan. To detect
degenerating neurons, the slides were fixated in 4% formalin
and immersed in 0.06% potassium permanganate (KMnO4) for
10min before being incubated for 30min in Fluoro Jade B. The
slides were dried at 50◦C, immersed in xylene for 15min and
mounted with Entellan.
Sections were first examined at 1x magnification through
a Nikon E600 microscope using dark field illumination. The
level of each examined coronal section was identified using
the 3rd edition of Paxinos and Watson’s rat brain atlas (18).
The lateral ventricles, anterior commissure and the shape
of the corpus callosum were used as landmarks. For COX-2
protein expression detection, eight sections per animal were
digitally photographed in 40x using dark field illumination in
a Nikon Eclipse E600 microscope. Eight whole brain sections
were photographed per animal. In the ipsilateral side one
picture was taken from the perilesional area and one from
the ventrolateral cortex, with corresponding areas being
photographed in the contralateral side. Thus, 32 pictures (four
pictures per brain section and eight sections per animal) were
analyzed for each animal. The integrated intensity of the COX-2
protein expression was analyzed in ImageJ. The following
macro-code was used as the batch process for automated
counting of the integrated intensity with a set threshold:
run(“8-bit”);run(“Invert”);setAutoThreshhold(“Yen”);//run
(“Threshold. . . ”); run(“Measure”);close();saveAs(“Results” . . . ).
Quantification of Fluoro Jade and TUNEL positive cells was done
manually in 40x magnification. Fluoro Jade positive cells were
counted in the ipsilateral and contralateral side of eight sections
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per animal. TUNEL positive cells were counted similarly in four
sections per animal. The lesion area was analyzed by Fiji/ImageJ
software from 1x dark field photographs.
Statistical Analyses
Statistical analyses were carried out in GraphPad Prism version
6.05 for Windows (GraphPad Software, La Jolla, USA). All error
bars represent the standard error of the mean (SEM). COX-2,
TUNEL and Fluoro Jade was analyzed by the non-parametric
Kruskal Wallis ANOVA followed by Benjamini Hochberg post-
hoc test. Lesion area was analyzed by two-way unpaired t-test.
p< 0.05 was considered significant. Significance levels: ∗p< 0.05,
∗∗∗p < 0.005.
RESULTS
COX-2 protein expression was increased in the ipsilateral
side following trauma, in both the “controls” and “diclofenac
treatment” groups compared to the “sham” and “normal”
(p < 0.05) groups. No differences were observed between the
“controls” and the “diclofenac” group. Weak COX-2 expression
was seen in the contralateral side in all groups except for “normal”
(Figures 2A–F). TUNEL positive cells were increased in the
injured hemispheres of the “diclofenac” and “control” groups
compared to the “sham” and “normal” groups. TUNEL positive
cells were not detected in the contralateral hemispheres. The
number of TUNEL positive cells were lower in the diclofenac
treatment group compared to the “control” group with a mean
change of 54% (“diclofenac” 39.8 cells/view—“control” 85.6
cells/view) (p < 0.05) (Figures 2G–L). Fluoro Jade positive cells
were increased in both the “diclofenac” and “control” groups
compared to “sham” and “normal.” Positive cells were not
detected in the contralateral sides. Furthermore, no differences
were detected between the different groups (Figures 2M–R). The
lesion area was measured in the groups exposed to penetrating
trauma. The lesion areas measured at six different levels were
significantly smaller at four levels and smaller with statistical
significance at four. Themean differences were 55% (“diclofenac”
9.2 mm2–“control” 16.9 mm2) (p < 0.005) (Figures 3A–S).
DISCUSSION
This study showed that specific COX-2 inhibition by diclofenac
was associated with decreased apoptosis in the perilesional area
after focal penetrating TBI. The focal penetrating TBI model
is highly reproducible and has a known gender specific COX-
2 response (12). In this specific context, the model mimics
an open brain contusion, which is a particular form of head
trauma (19). This kind of injury allowed direct intralesional
administration of diclofenac. The mode of administration is
unusual but provides direct access to the intended target area
and reduces the risk of a heterogenous uptake in the brain
from intravenously or intraperitoneally injected substances.
Intralesional administration in the brain is not standard clinical
practice in head injuries, which may comprise a limitation
of the clinical applicability. Direct administration into surgical
sites is, however, practiced with gliadel wafers for brain tumor
therapy and antibiotics for management of ventriculitis; hence
intra-axial administration for clinical focal brain injuries should
be considered as a novel clinical option. There are potential
risks associated with intralesional administration of a vasoactive
substance, and coagulation derangements including a possible
higher risk of hemorrhage. Safety needs to be addressed in
clinical studies since our study only intended to analyse the
impact of COX-2 inhibition on cell death; the large effect size
that may foster hopes of neuroprotection was not expected. We
targeted the immediate inflammation known to occur 24 h after
TBI (14) and found important differences probably caused by
diclofenac treatment. Yet, the present study cannot determine the
precise effects of diclofenac; a complete time series is necessary to
evaluate final cell survival and comprehensive kinetics.
COX-2 was upregulated in the perilesional area after TBI,
similarly to our experience (12) and previous reports (8,
10, 20–22). Most expression was found in the ipsilateral
hemisphere, with little expression also in the contralateral side.
Diclofenac did not decrease protein expression of COX-2.
Earlier studies report conflicting results of COX inhibition. The
COX-2 inhibitor rofecoxib did not alter the COX-2 expression
(21), while the COX-2 inhibitor DFU decreased COX-2 when
the drug was administered 10min before trauma, but not
when administered 2–6 h post trauma (10). It is possible that
systemic inflammation in the body is sufficient for general
COX-2 induction, and that the acute blood brain barrier
disruption by the focal injury allowed for COX-2 to enter
the brain.
TUNEL staining, indicative of apoptosis was increased in
the perilesional area in all trauma groups compared to the
“sham” group. Diclofenac decreased TUNEL staining compared
to “control.” The number of neurons positive for Fluoro Jade
were increased after TBI, although they were not affected
by diclofenac. Fluoro Jade labels degeneration, both necrosis
and apoptosis, while TUNEL staining is specific in labeling
apoptosis (23). Fluoro Jade is specific in labeling neurons,
while TUNEL labels all cell types undergoing apoptosis. It
is therefore possible that the inflammatory amelioration by
diclofenac occurs primarily in cells other than neurons. It is
also possible that high levels of neuronal necrosis resulting from
the penetrating injury conceals possible anti-apoptotic effects
in the neurons specifically. DFU decreased activated caspase-
3 levels, further suggesting specific antiapoptotic effects (10),
while no effects on TUNEL or Fluoro Jade staining were detected
after rofecoxib treatment following rodent fluid percussion TBI
(21). Potentially, COX-2 inhibition is more effective in specific
TBI subgroups, which should be explored in future studies. The
amount of TUNEL positive cells in the “control” group (male
rats) corresponded to the amount found in male rat brains
when comparing male and female responses in an identical
setting in the preceding study (12). TUNEL positive cells in the
“diclofenac” group also corresponded to the amount in untreated
female rats exposed to identical trauma. It is possible that lower
levels of COX-2 in female brains is protective, and that male
subgroups should be targeted in future studies of neuroprotective
properties of diclofenac. TUNEL positive cells in the “control”
(NaCl vehicle) group corresponded to the amount in male rats
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FIGURE 2 | (A) COX-2 protein expression was upregulated 24 h following injury. Diclofenac did not affect protein expression. Photomicrographs of COX-2
fluorescence (B) “normal” ipsilateral (C) “sham” ipsilateral (D) “control” trauma ipsilateral (E) “diclofenac” treated trauma ipsilateral. (F) Contralateral side (G) TUNEL
staining showing lower apoptosis levels by diclofenac treatment. Photomicrographs of TUNEL (H) “normal” ipsilateral (I) “sham” ipsilateral (J) “control” trauma
ipsilateral (K) “diclofenac” treated trauma ipsilateral. (L) Contralateral side (M) diclofenac treatment did not affect Fluoro Jade detected neuronal degeneration.
Photomicrographs of Fluoro Jade (N) “normal” ipsilateral (O) “sham” ipsilateral (P) “control” trauma ipsilateral (Q) “diclofenac” treated trauma ipsilateral. (R)
Contralateral side. Data expressed as mean ± SEM. *p < 0.05.
receiving no injection in the preceding study (12), why possible
cell death resulting from the injection only could be excluded.
Diclofenac appeared to decrease the macroscopic lesion area
after 24 h. We could only quantify and compare the lesion areas
in a limited number of brain sections which were available
after the immunohistochemical analyses; the extensive effect
on lesion size was unexpected and serendipitous. We did not
have material to make a three-dimensional analysis of the
lesion volume, which comprised a limitation. The size effect
was, however, extensive from the analyses we made and the
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FIGURE 3 | (A–S) Diclofenac treatment decreased lesion area in the frontal perilesional area. Lesion area was measured at comparable sections at bregma +0.48,
+0.7, +1.0, +1.2, +1.6, +1.7mm (black arrows) representing the frontal part of the perilesional area. Data expressed as mean ± SEM. *p < 0.05, ***p < 0.005.
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intralesional treatment needs to be evaluated with prospective
quantification of lesion volumes. Similar results of COX-2
inhibition reducing lesion size together with increased glia
cell proliferation in the perilesional area have been reported
(9). It is therefore possible that the anti-apoptotic and tissue
sparing effects were not a direct effect by COX-2 inhibition
but mediated by other cells. Microglial activation occurs within
24 h after experimental TBI (24). Sites of activation often
coincide with neuronal degeneration and axonal abnormality,
hence anti-inflammatory treatments targeting microglia are
suggested as potential therapeutic strategies (25). It is also
feasible that astrocytes mediate apoptosis. Astrocytes maintain
the homeostasis of ions, transmitters, water, and blood flow,
critical for neuronal function. In response to TBI, astrocytes
become active in response to axonal injury, vascular disruption,
ischemia and inflammation (26), and are emerging as both potent
pro-inflammatory and anti-inflammatory cells (27). Astrocytes
are associated with T-cell apoptosis in autoimmune inflammation
(28). Future studies should therefore aim at investigating specific
apoptotic pathways and the effect of diclofenac on neurons as
well as glia cells. These studies may also target protein markers of
axonal functionality, such as phosphorylated neurofilaments to
determine if diclofenac in addition to reducing cell death favors
the restoration of axonal functionality decreased by injury.
The findings suggest that the gender-related difference in
apoptotic cells after TBI (12) is associated with COX-2 regulation.
Most anti-inflammatory drugs have failed to produce lasting
effects (29). It is possible that COX-2 inhibition is beneficial in
focal TBI, making diclofenac a potential candidate for further
clinical applications. In addition, local administration of the drug
may provide a novel treatment that can be developed clinically.
CONCLUSION
COX-2 inhibition by diclofenac is associated with decreased
apoptosis after focal penetrating TBI and may be beneficial in
preventing brain tissue damage.
ETHICS STATEMENT
Swedish regional ethics approval board for animal
research (N81/13).
AUTHOR CONTRIBUTIONS
MG, MR, JD, and TM planned the study. MG, JD, and KD
performed the experiments. KD, EL, MA, and AH performed
preparation and analysis. All authors contributed to the text.
FUNDING
The study was funded by the Swedish Defense.
REFERENCES
1. Maas AI, Stocchetti N, Bullock R. Moderate and severe
traumatic brain injury in adults. Lancet Neurol. (2008) 7:728–41.
doi: 10.1016/S1474-4422(08)70164-9
2. Woodcock T, Morganti-Kossmann MC. The role of markers of
inflammation in traumatic brain injury. Front Neurol. (2013) 4:18.
doi: 10.3389/fneur.2013.00018
3. Adelson PD, Dixon CE, Robichaud P, Kochanek PM. Motor and
cognitive functional deficits following diffuse traumatic brain injury in
the immature rat. J Neurotrauma. (1997) 14:99–108. doi: 10.1089/neu.199
7.14.99
4. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J
Lipid Res. (2009) 50(Suppl.):S29–34. doi: 10.1194/jlr.R800042-JLR200
5. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and
degenerative brain diseases. J Neuropathol Exp Neurol. (2004) 63:901–10.
doi: 10.1093/jnen/63.9.901
6. Ku EC, Lee W, Kothari HV, Scholer DW. Effect of diclofenac
sodium on the arachidonic acid cascade. Am J Med. (1986) 80:18–23.
doi: 10.1016/0002-9343(86)90074-4
7. Gan TJ. Diclofenac: an update on its mechanism of action and safety
profile. Curr Med Res Opin. (2010) 26:1715–31. doi: 10.1185/03007995.2010.4
86301
8. Cernak I, O’Connor C, Vink R. Inhibition of cyclooxygenase 2 by
nimesulide improves cognitive outcome more than motor outcome following
diffuse traumatic brain injury in rats. Exp Brain Res. (2002) 147:193–9.
doi: 10.1007/s00221-002-1245-z
9. Thau-Zuchman O, Shohami E, Alexandrovich AG, Trembovler V, Leker
RR. The anti-inflammatory drug carprofen improves long-term outcome
and induces gliogenesis after traumatic brain injury. J Neurotrauma. (2012)
29:375–84. doi: 10.1089/neu.2010.1673
10. Gopez JJ, Yue H, Vasudevan R, Malik AS, Fogelsanger LN, Lewis
S, et al. Cyclooxygenase-2-specific inhibitor improves functional
outcomes, provides neuroprotection, and reduces inflammation in a
rat model of traumatic brain injury. Neurosurgery. (2005) 56:590–604.
doi: 10.1227/01.NEU.0000154060.14900.8F
11. Gupte R, Brooks WM, Vukas RR, Pierce JD, Harris JL. Sex differences
in traumatic brain injury: What we know and what we should know. J
Neurotrauma. (2019). doi: 10.1089/neu.2018.6171. [Epub ahead of print].
12. Günther M, Plantman S, Davidsson J, Angéria M, Mathiesen T, Risling
M. COX-2 regulation and TUNEL-positive cell death differ between
genders in the secondary inflammatory response following experimental
penetrating focal brain injury in rats. Acta Neurochirurgica. (2015) 157:649–
59. doi: 10.1007/s00701-014-2331-2
13. Plantman S, Ng KC, Lu J, Davidsson J, Risling M. Characterization of a
novel rat model of penetrating traumatic brain injury. J Neurotrauma. (2012)
29:1219–32. doi: 10.1089/neu.2011.2182
14. Bains M, Hall ED. Antioxidant therapies in traumatic brain and
spinal cord injury. Biochim Biophys Acta. (2011) 1822:675–84.
doi: 10.1016/j.bbadis.2011.10.017
15. Deng Y, Thompson BM, Gao X, Hall ED. Temporal relationship of
peroxynitrite-induced oxidative damage, calpain-mediated cytoskeletal
degradation and neurodegeneration after traumatic brain injury. Exp Neurol.
(2007) 205:154–65. doi: 10.1016/j.expneurol.2007.01.023
16. Björkman R. Central antinociceptive effects of non-steroidal
anti-inflammatory drugs and paracetamol. Experimental studies
in the rat. Acta Anaesthesiol Scand Suppl. (1995) 103:1–44.
doi: 10.1111/j.1399-6576.1995.tb04249.x
17. Björkman RL, Hedner T, Hallman KM, Henning M, Hedner J. Localization
of the central antinociceptive effects of diclofenac in the rat. Brain Res. (1992)
590:66–73. doi: 10.1016/0006-8993(92)91082-P
18. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 7th ed.
Cambridge, MA: Academic Press (2013).
19. Mathiesen T, Kakarieka A, Edner G. Traumatic intracerebral lesions without
extracerebral haematoma in 218 patients. Acta Neurochir. (1995) 137:155–63;
discussion 163. doi: 10.1007/BF02187188
Frontiers in Neurology | www.frontiersin.org 7 July 2019 | Volume 10 | Article 811
Dehlaghi Jadid et al. Intralesional Administration of Diclofenac
20. Dash PK, Mach SA, Moore AN. Regional expression and role of
cyclooxygenase-2 following experimental traumatic brain injury. J
Neurotrauma. (2000) 17:69–81. doi: 10.1089/neu.2000.17.69
21. Kunz T, Marklund N, Hillered L, Oliw EH. Effects of the selective
cyclooxygenase-2 inhibitor rofecoxib on cell death following traumatic brain
injury in the rat. Restor Neurol Neurosci. (2006) 24:55–63.
22. Girgis H, Palmier B, Croci N, Soustrat M, Plotkine M, Marchand-
Leroux C. Effects of selective and non-selective cyclooxygenase inhibition
against neurological deficit and brain oedema following closed head
injury in mice. Brain Res. (2013) 1491:78–87. doi: 10.1016/j.brainres.2012.
10.049
23. Negoescu A, Guillermet C, Lorimier P, Brambilla E, Labat-Moleur
F. Importance of DNA fragmentation in apoptosis with regard
to TUNEL specificity. Biomed Pharmacother. (1998) 52:252–8.
doi: 10.1016/S0753-3322(98)80010-3
24. Günther M, Davidsson J, Plantman S, Norgren S, Mathiesen
T, Risling M. Neuroprotective effects of N-acetylcysteine
amide on experimental focal penetrating brain injury in rats.
J Clin Neurosci. (2015) 22:1477–83. doi: 10.1016/j.jocn.2015.
03.025
25. Donat CK, Scott G, Gentleman SM, Sastre M. Microglial activation
in traumatic brain injury. Front Aging Neurosci. (2017) 9:208.
doi: 10.3389/fnagi.2017.00208
26. Burda JE, Bernstein AM, Sofroniew MV. Astrocyte roles in traumatic brain
injury. Exp Neurol. (2016) 275(Pt 3):305–15. doi: 10.1016/j.expneurol.2015.
03.020
27. Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev
Neurosci. (2015) 16:249–63. doi: 10.1038/nrn3898
28. Steelman AJ, Smith R, Welsh CJ, Li J. Galectin-9 protein is up-regulated
in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell
apoptosis. J Biol Chem. (2013) 288:23776–87. doi: 10.1074/jbc.M113.451658
29. Maas AI, Menon DK. Traumatic brain injury: rethinking
ideas and approaches. Lancet Neurol. (2012) 11:12–3.
doi: 10.1016/S1474-4422(11)70267-8
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Dehlaghi Jadid, Davidsson, Lidin, Hånell, Angéria, Mathiesen,
Risling and Günther. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 8 July 2019 | Volume 10 | Article 811
